XTX Topco Ltd Makes New $121,000 Investment in Zymeworks Inc. (NYSE:ZYME)

XTX Topco Ltd acquired a new stake in shares of Zymeworks Inc. (NYSE:ZYME) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm acquired 14,272 shares of the company’s stock, valued at approximately $121,000.

A number of other large investors also recently modified their holdings of ZYME. Rubric Capital Management LP grew its holdings in Zymeworks by 31.1% during the 4th quarter. Rubric Capital Management LP now owns 3,475,384 shares of the company’s stock valued at $36,109,000 after buying an additional 823,990 shares in the last quarter. Vanguard Group Inc. grew its stake in Zymeworks by 2.6% during the first quarter. Vanguard Group Inc. now owns 2,458,105 shares of the company’s stock valued at $25,859,000 after acquiring an additional 63,393 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Zymeworks by 1.2% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,930,887 shares of the company’s stock valued at $16,431,000 after acquiring an additional 23,173 shares during the last quarter. Acadian Asset Management LLC lifted its stake in Zymeworks by 4.1% in the 1st quarter. Acadian Asset Management LLC now owns 1,305,057 shares of the company’s stock worth $13,724,000 after purchasing an additional 51,036 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its stake in Zymeworks by 94.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 716,482 shares of the company’s stock worth $7,537,000 after purchasing an additional 348,441 shares in the last quarter. Hedge funds and other institutional investors own 92.89% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. Stifel Nicolaus lifted their target price on Zymeworks from $20.00 to $21.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. HC Wainwright lifted their price objective on Zymeworks from $10.00 to $12.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 25th.

Zymeworks Stock Down 1.6 %

Zymeworks stock opened at $12.35 on Wednesday. The company’s 50-day moving average price is $11.33 and its 200-day moving average price is $9.94. The company has a market cap of $873.21 million, a PE ratio of -6.90 and a beta of 1.19. Zymeworks Inc. has a twelve month low of $6.01 and a twelve month high of $13.27.

Zymeworks (NYSE:ZYME) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.01. The company had revenue of $19.24 million for the quarter, compared to analysts’ expectations of $23.16 million. Zymeworks had a negative return on equity of 21.97% and a negative net margin of 179.42%. During the same period in the previous year, the firm posted ($0.76) earnings per share. As a group, sell-side analysts expect that Zymeworks Inc. will post -0.85 earnings per share for the current fiscal year.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.